Danielle Antalffy
Stock Analyst at UBS
(1.60)
# 846
Out of 4,827 analysts
163
Total ratings
40.43%
Success rate
-8.48%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRC AtriCure | Maintains: Buy | $60 → $58 | $31.18 | +86.02% | 13 | Apr 30, 2025 | |
| INMD InMode | Maintains: Neutral | $19 → $16 | $14.23 | +14.20% | 4 | Apr 29, 2025 | |
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $13.23 | +20.94% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $83.62 | +13.61% | 8 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $103.29 | +25.86% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $3.00 | +66.67% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $134.00 | +10.45% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $90.54 | +101.02% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $382.46 | -3.26% | 6 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $74.63 | +0.50% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $112 → $107 | $95.11 | +12.50% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $7 | $7.54 | -7.16% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $85.34 | +11.32% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $33.08 | +126.72% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $155.66 | +15.64% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $152.79 | +110.75% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.27 | -0.88% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $31.20 | +37.82% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $538.16 | -48.34% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $22.74 | +97.89% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $257.00 | +8.95% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $15.88 | +5,095.21% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $12.59 | +11.20% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $80.44 | +24.32% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $12.58 | -4.61% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $54.81 | -45.27% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.87 | +7.48% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $167.95 | +63.74% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $5.34 | +274.53% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.35 | +561.42% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.74 | +307.17% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.87 | +1,624.14% | 1 | Sep 1, 2020 |
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $31.18
Upside: +86.02%
InMode
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $14.23
Upside: +14.20%
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $13.23
Upside: +20.94%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $83.62
Upside: +13.61%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $103.29
Upside: +25.86%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $3.00
Upside: +66.67%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $134.00
Upside: +10.45%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $90.54
Upside: +101.02%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $382.46
Upside: -3.26%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $74.63
Upside: +0.50%
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $95.11
Upside: +12.50%
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $7.54
Upside: -7.16%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $85.34
Upside: +11.32%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $33.08
Upside: +126.72%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $155.66
Upside: +15.64%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $152.79
Upside: +110.75%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.27
Upside: -0.88%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $31.20
Upside: +37.82%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $538.16
Upside: -48.34%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $22.74
Upside: +97.89%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $257.00
Upside: +8.95%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $15.88
Upside: +5,095.21%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $12.59
Upside: +11.20%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $80.44
Upside: +24.32%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $12.58
Upside: -4.61%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $54.81
Upside: -45.27%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.87
Upside: +7.48%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $167.95
Upside: +63.74%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $5.34
Upside: +274.53%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.35
Upside: +561.42%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.74
Upside: +307.17%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.87
Upside: +1,624.14%